Shares of Brainsway BWAY, +18.96% are up 10% in premarket trading on positive trial results for its brain stimulation device as a smoking cessation tool for longtime chronic cigarette smokers. About 20% of the patients in the study who completed treatment reported a four-week continuous quit rate, compared to 8% in the placebo group. “The success demonstrated in this study in treating patients addicted to cigarettes strengthens our optimism with respect to the potential for the use of our platform technology to treat other addictions as well,” Brainsway interim CEO David Zacut said in a news release. The Israeli medical device maker went public in April. Its stock has fallen 8% over the last three months, while the S&P 500 SPX, -0.83% has gone up 7% during the same period.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.